UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
UCB will present a broad set of myasthenia gravis data at the 2026 AANEM Annual Meeting and MGFA Scientific Session in Orlando, September 29 to October 2. Highlights include 120-week post hoc analyses showing minimal symptom expression with ZILBRYSQ (zilucoplan) and RYSTIGGO (rozanolixizumab-noli), reinforcing long-term durability of its commercialized gMG franchise. Early interim Phase 1b data will also be shown for cizutamig, an investigational BCMA×CD3 T-cell engager acquired via the Candid Therapeutics purchase; it is not FDA approved.
Key figures
- Drug Name
- cizutamig (BCMA×CD3 T-cell engager)
- Phase Of Trial
- Phase 1b
- Revenue 2025
- €7.7 billion
- Long term data duration
- 120-week post hoc analysis of RAISE-XT (zilucoplan)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.